Cathay Biotech Current Valuation vs. Market Capitalization
| 688065 Stock | 42.84 0.22 0.51% |
For Cathay Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cathay Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cathay Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cathay Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cathay Biotech over time as well as its relative position and ranking within its peers.
Cathay |
Cathay Biotech Market Capitalization vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cathay Biotech's current stock value. Our valuation model uses many indicators to compare Cathay Biotech value to that of its competitors to determine the firm's financial worth. Cathay Biotech is rated below average in current valuation category among its peers. It also is rated below average in market capitalization category among its peers creating about 1.15 of Market Capitalization per Current Valuation. Comparative valuation analysis is a catch-all model that can be used if you cannot value Cathay Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cathay Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Cathay Current Valuation vs. Competition
Cathay Biotech is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Materials industry is presently estimated at about 1.86 Trillion. Cathay Biotech claims roughly 21.65 Billion in current valuation contributing just under 2% to all equities under Materials industry.
Cathay Market Capitalization vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Cathay Biotech |
| = | 21.65 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Cathay Biotech |
| = | 24.79 B |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Cathay Market Capitalization vs Competition
Cathay Biotech is rated below average in market capitalization category among its peers. Market capitalization of Materials industry is presently estimated at about 1.35 Trillion. Cathay Biotech claims roughly 24.79 Billion in market capitalization contributing just under 2% to all equities under Materials industry.
Cathay Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cathay Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cathay Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Cathay Biotech's change in net profit over the period of time. It can combine multiple indicators of Cathay Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 181.9 M | 134.7 M | |
| Interest Income | 219.8 M | 156.9 M | |
| Operating Income | 273.3 M | 371.7 M | |
| Net Income From Continuing Ops | 408.5 M | 570 M | |
| Income Before Tax | 448.9 M | 471.4 M | |
| Net Income | 366.5 M | 394.3 M |
Cathay Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cathay Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cathay Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cathay Biotech's important profitability drivers and their relationship over time.
Use Cathay Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cathay Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cathay Biotech will appreciate offsetting losses from the drop in the long position's value.Cathay Biotech Pair Trading
Cathay Biotech Pair Trading Analysis
The ability to find closely correlated positions to Cathay Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cathay Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cathay Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cathay Biotech to buy it.
The correlation of Cathay Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cathay Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cathay Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cathay Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cathay Biotech position
In addition to having Cathay Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Beers Thematic Idea Now
Beers
Companies involved in production and distribution of domestic and international beer. The Beers theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beers Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Cathay Stock
To fully project Cathay Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cathay Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cathay Biotech's income statement, its balance sheet, and the statement of cash flows.